SCHEMBL140533

SCHEMBL140533

COc1ccc(-c2nc(C(N)=O)c3[nH]c4cc(OC)ccc4c3n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 1.00
CSNK2A1 P68400 5/20 0.51
CSNK2A2 P19784 1/20 0.51
CSNK2B P67870 1/20 0.51
DYRK1A Q13627 4/20 0.47
CLK1 P49759 2/20 0.47
CDK5 Q00535 2/20 0.47
CDK5R1 Q15078 2/20 0.47
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
EIF2AK2 P19525 1/20 0.45
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
CHEK2 O96017 2/20 0.43
PARP1 P09874 1/20 0.43
PLA2G2A P14555 1/20 0.43
ALOX15 P16050 1/20 0.43
PTGS2 P35354 1/20 0.43
BTK Q06187 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144484 0.89 JAK2 (0.80) JAK2DYRK1ACLK1CDK5CDK5R1
SCHEMBL178661 0.81 JAK2 (0.67) JAK2DYRK1ACLK1CDK5CDK5R1
SCHEMBL142463 0.80 JAK2 (0.77) JAK2DYRK1ACLK1CDK5CDK5R1
SCHEMBL142655 0.74 JAK2 (0.78) JAK2DYRK1ABCHEACHEALDH1A1
SCHEMBL141522 0.73 JAK2 (0.80) JAK2DYRK1ABCHEACHEALDH1A1
SCHEMBL141989 0.73 JAK2 (0.68) JAK2PARP1
SCHEMBL25832011 0.72 DYRK1A (0.79) JAK2DYRK1ACLK1CDK5CDK5R1
SCHEMBL30199348 0.72 DYRK1A (0.79) JAK2DYRK1ACLK1CDK5CDK5R1
SCHEMBL142234 0.71 JAK2 (0.68) JAK2DYRK1ACLK1CDK5CDK5R1
SCHEMBL143862 0.71 JAK2 (1.00) JAK2DYRK1ABCHEACHEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885CSNK2A1 21/4885CSNK2A2 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.